

Docket No. 22338-602	Application No. 09/613,038
Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
Filing Date: July 10, 2000	Group Art Unit: 1636

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			OTHER DOCUMENTS (Including Author, Title, Date, Fertinent Fages, Etc.)
<u>.</u> نون	. 1	76	Alawyn IPJ, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, et al. Effects of Specific Anti-B
in	H -		and/or Anti-Plasma Cell Immunotherapy on Antibody Production in Baboons: Depletion of
١			CD20- and CD22-Positive B Cells Does Not Result in Significantly Reduced Production of
			Anti-Gal Antibody. Xenotransplantation 2001; 8:157-171.
	1	77	Aranda JM, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, et al. Anti-CD20
			Monoclonal Antibody (Rituximab) Therapy for Acute Cardiac Humoral Rejection: A Case
• 1			Report. Transplantation 2002; 73:907-910.
	1	78	Agarwal A, Vieira C, Book B, Fineberg N, Sidner R, Ochs H, et al. Rituximab, Anti-CD20
Inhibits a Human in Vivo Primary and Secondary Antibody Response to B		Inhibits a Human in Vivo Primary and Secondary Antibody Response to Bacteriophage	
			PhiX174. Blood 2001; 98:608a.
	1	79	Agarwal A, Vieira CA, Book BK, Zeni T, Sidner RA, Fineberg NA, et al. Effect of Rituximab
			on Natural Antibodies in Pre-Transplant Patients. American Journal Transplant 2002; 2 (Suppl.
			3):345.
	1	80	Garrett HE, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of Humoral
			Rejection with Rituximab. Ann. Thoracic Surgeon 2002; 74:1240-1242.
	1	81	Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL, et al. Overcoming a
			Positive Crossmatch in Living-Donor Kidney Transplantation. American Journal
			Transplantation 2003; 3:1017-1023.
	1	82	Monteiro I, McLoughlin LM, Fisher A, de la Torre AN, Koneru B. Rituximab with
			Plasmapheresis and Splenectomy in ABO-Incompatible Liver Transplantation. Transplantation
.			2003; 76:1648-1649.
	1	83	Pierson RN, Loyd JE, Goodwin A, Majors D, Dummer JS, Mohacsi P, et al. Successful
			Management of an ABO-Mismatched Lung Allograft Using Antigen-Specific
			Immunoadsorption, Complement Inhibition, and Immunomodulatory Therapy.
			Transplantation 2002; 74:79-84.
$ \cdot $	1	84	Sammartino C, Pham T, Panaro F, Bogetti D, Jarzembowski T, Sankary H, et al. Successful
			Simultaneous Pancreas Kidney Transplantation from Living-Related Donor Against Positive
			Cross-Match. American Journal Transplantation 2004; 4:140-143.
	1	85	Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. Rituximab for
)			Reduction of HLA Antibodies in Patients Awaiting Renal Transplantation: Pattern of B Cell
			Recovery. FASEB J 2003; 17:C113.
	1	86	Tyden G, Kumlien G, Fehrman I. Successful ABO-Incompatible Kidney Transplantations
			without Splenectomy Using Antigen-Specific Immunoadsorption and Rituximab.
4	1	]	Transplantation 2003; 76:730-731.
		87	Vieira CA, Agarwal A, Book BK, Sidner RA, Zeni T, Gebel HM, et al. Rituxan for Reduction
mt	)		of Anti-HLA Antibodies in Patients Awaiting Renal Transplantation. American Journal
			Transplantation 2002; 2:356.

EXAMINER Maker Hodged	DATE CONSIDERED 7/14/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609;				
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to				
applicant.				
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 2			

JUN 16 2004	[H]	-
A. our	Vocket No. 22338-602	Application No. 09/613,038
INFORMATION DISCLOSURE STATEMENT	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
SIATEMENT	Filing Date: July 10, 2000	Group Art Unit: 1636

	188	Becker YT, Becker BN, Knechtle SJ, Odorico JS, D'Alessandro AM, Pirsch JD, Sollinger HW.
mH		Treatment of Steroid Resistant Rejection with a Novel Anti-B-cell Preparation, Rituximab.
1,112		Transplantation 2000; 69 (8 Suppl.): S362.
189 Essell JH, Broun ER, Sigmund D, Tierney C, Devoe M, H		Essell JH, Broun ER, Sigmund D, Tierney C, Devoe M, Heying K, et al. Treatment of
\	!	Refractory Chronic Graft-vs-Host Disease with Infliximab. Procedure American Society
\		Clinical Oncology 2003; 22:836.
190 McGuirk J, Dix S, Belt R. Rituximab and Immune Modulation Post Unrelated		McGuirk J, Dix S, Belt R. Rituximab and Immune Modulation Post Unrelated Donor
		Transplant as Treatment for Refractory Burkitt's-Lke Lmphoma. Blood 2000; 96 (Suppl
. \		2):242b.
	191	Pivkova A, Georgievski B, Cevreska L, Panovska I, Stojanovski Z, Krstevska-Balkanov S, et
		al. Rituximab in the Treatment of Chronic Extensive Graft Versus Host Disease: Case Report.
		Presented at the 8th Annual Conference of the European Haematology Association, June 12-
		15, Lyon, France, 2003.
	192	Sawada T, Fuchinoue S. Teraoka S. Successful A1-to-0 ABO-Incompatible Kidney
		Transplantation After a Preconditioning Regimen Consisting of Anti-CD20 Monoclonal
		Antibody Infusions, Splenectomy, and Double-filtration Plasmapheresis. Transplantation
		2002; 74:1207-1210
	193	Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease.
		Bone Marrow Transplant 2001;28:121-129.
	194	Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, et al. Anti-CD20
		Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated
		Thrombocytopenia in a Patient with Chronic Graft-Versus-Host Disease. Ann Intern Med
		2000;133:275-279.
	195	Ratanatharathorn V, Bociek RG, Pavletic SZ, Lynch JC, Ferrara JL, Uberti JP. Prior Therapy
		with Anti-CD20 Chimeric Antibody (Rituximab) May Decrease the Risk of Acute Graft-
•		Versus-Host Disease (GVHD) in Patients with Non-Hodgkin's Lymphoma Receiving
	Allogeneic Stem Cell Transplantation. Blood 2000; 96:391a.	
• /	196	Szabolcs P, Reese M, Yancey K, Hall R, Joanne K. Combination Treatment of Bullous Skin
	GHVD With Anti-CD20 and Anti-CD25 Antibodies. Blood 2000; 96 (Suppl 2):350b.	
7	197	Thomson J, Vassiliou G, Veys P, Redmill B, Edelsten C. Epstein-Barr Virus Dacryoadenitis as
	a Complication of Bone Marrow Transplant in a Child with Combined Immunodeficiency. Ex	
4		2001;15:815-816.
MΗ	198	Letter from Dr. Paul F. Fehlner Dated May 27, 2004

EXAMINER Maher Haddad	DATE CONSIDERED 7/19/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609;				
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to				
applicant.				
Form PTO-A820 (also form PTO-1449)	SHEET 2 OF 2			